IDEXX Raises 2026 EPS Guidance to $14.69-$14.94 After Strong Q2 Beat
IDXX is trading near its 52-week low of $518.55 (13% above the low) on elevated volume (2.3× avg).
Summary
IDEXX Laboratories reported Q2 2026 revenue of $1.217 billion and diluted EPS of $4.27, both above expectations, and raised full-year EPS guidance to $14.69-$14.94. Strong cash flow funded nearly $700 million in share repurchases.
Key Events · Earnings and Guidance · IDXX
-
Q2 Revenue and EPS Beat
Revenue grew 9.7% to $1.217 billion; diluted EPS of $4.27 exceeded expectations, driven by 10.3% organic growth in CAG Diagnostics recurring revenue.
-
Full-Year Guidance Raised
Management increased 2026 EPS guidance to $14.69-$14.94, up from prior expectations, citing strong volume and price realization across segments.
-
Gross Margin Expansion
Gross margin improved 140 bps to 64.0%, benefiting from favorable mix shift toward higher-margin consumables and reference lab services, and operational productivity.
-
Operating Cash Flow Surge
H1 2026 operating cash flow reached $613.4 million, up 45% YoY, driven by higher net income and a $77.9 million reduction in cash used for working capital versus the prior year.
Analysis · IDXX · Life Sciences
IDEXX delivered a strong Q2, with revenue up 9.7% and diluted EPS of $4.27 beating expectations. Gross margin expanded 140 basis points to 64%, driven by favorable mix and productivity. Management raised full-year 2026 EPS guidance to $14.69-$14.94, reflecting confidence in sustained demand for companion animal diagnostics. Operating cash flow surged to $613.4 million in the first half, up 45% year-over-year, providing ample capacity for the $692.9 million in share repurchases executed at an average price of $592.41. The company also amended supply agreements with Ortho-Clinical Diagnostics to support SDMA slide packaging, reinforcing its diagnostic menu expansion. With a net debt to EBITDA ratio of just 0.46x and $729 million in available credit, IDEXX has significant financial flexibility to continue returning capital to shareholders while investing in growth.
At the time of this filing, IDXX was trading at $588.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $46.4B. The 52-week trading range was $518.55 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.